期刊文献+

EGFR信号通路基因突变与非小细胞肺癌的靶向性治疗 被引量:5

下载PDF
导出
摘要 表皮生长因子受体(EGFR)是酪氨酸激酶活性的受体,由配体激活后,调解上皮细胞的生长分化。近年来研究发现有62%的非小细胞肺癌患者存在EGFR高表达和异常激活。针对EG-FR突变研发的靶向治疗药物——吉非替尼、埃罗替尼已通过美国FDA验证用于临床,但是存在不同程度的耐药。可见,决定非小细胞肺癌(NSCLC)对酪氨酸激酶受体抑制剂(TKI)——Gefitinib,Erlotinib敏感性的突变基因不仅仅只有EGFR基因,其存在复杂的基因突变谱。本文就目前对NSCLC基因突变类型与靶向治疗的研究进展作一综述。
出处 《国际检验医学杂志》 CAS 2009年第9期869-871,共3页 International Journal of Laboratory Medicine
基金 重庆市科技攻关计划项目(2007AC5067)
  • 相关文献

参考文献13

  • 1Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer[J].Cancer Sci 2007,98(12) :1817-1824.
  • 2吴健虹,谢秋玲,陈小佳,洪岸.表皮生长因子受体EGFR及其信号传导[J].生命科学,2006,18(2):116-122. 被引量:40
  • 3Marks JL, McLellan MD,Zakowski MF, et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenoeareb nomas identifies a novel somatic kinase domain mutation in FGFR4[J]. PLOS ONE,2007,2(5) :e426.
  • 4Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer [J ]. Int J Clin Oncol, 2006,11(3) : 190-198.
  • 5宋启斌,胡胜.EGFR突变与非小细胞肺癌[J].中国肿瘤,2007,16(11):910-914. 被引量:6
  • 6Mitsudomi T,Kosaka T,Endoh H,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence[J]. J Clin Oncol, 2005, 23 ( 11 ) : 2513- 2520.
  • 7Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small- cell-lung cancer[J]. J Natl Cancer Inst,2005,97(9) :643-655.
  • 8王俊,郭燕,陈正堂.肺癌EGFR突变与酪氨酸激酶抑制剂临床敏感性的关系[J].生命的化学,2006,26(5):443-445. 被引量:2
  • 9Sharma SV,Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer, 2007, 7 (3) :169q81.
  • 10Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications[J]. Cancer Res, 2004,64(24) : 8919-8923.

二级参考文献69

  • 1胡胜,宋启斌.非小细胞肺癌的靶向性治疗[J].中国肿瘤,2006,15(7):457-461. 被引量:4
  • 2Reiter J L,Threadgill D W,Eley G D,et al.Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms.Genomics,2001,71(1):1~20.
  • 3Ullrich A,Coussens L,Hayflick J S,et al.Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A341 epidermoid carcinoma cells.Nature,1984,309(5967):418~425.
  • 4Bishayee S.Role of conformational alteration in the epidermal growth factor receptor (EGFR) function.Biochem Pharmacol,2000,60(8):1217~1223.
  • 5Garrett T P J,McKern N M,Lou M,et al.Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α.Cell,2002,110:763~773.
  • 6Lemmon M A,Bu Z M,Ladbury J E,et al.Two EGF molecules contribute additively to stabilization of the EGFR dimmer.EMBO J,1997,16(2):281~294.
  • 7Abe Y,Odaka M,Inagaki F,et al.Disulfide bond structure of human epidermal growth factor receptor.J Biol Chem,1998,273(18):11150~11157.
  • 8Zhu H J,Jaria J,Orchard S,et al.Epidermal growth factor receptor:association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand.Growth Factors,2003,21(1):15~30.
  • 9Aifa S,Aydin J,Nordvall G,et al.A basic peptide within the juxtamembrane region is required for EGF receptor dimerization.Exp Cell Res,2005,302(1):108~114.
  • 10Bishayee A,Beguinot L,Bishayee S.Phosphorylation of tyrosine 992,1068,and 1086 is required for conformational change of the human epidermal growth factor receptor Cterminal tail.Mol Biol Cell,1999,10(3):525~536.

共引文献44

同被引文献48

  • 1贾正才,吴玉章.肿瘤抗原MAGE-A3研究进展[J].免疫学杂志,2001,17(z1):28-31. 被引量:12
  • 2刘凤安,王秀清.VEGF、EGFR蛋白表达与鼻咽癌浸润和转移[J].山东大学耳鼻喉眼学报,2006,20(3):227-229. 被引量:7
  • 3李秋泽,董子明,赵国强,彭培立,赵洁.黑色素瘤抗原基因MAGE-1、MAGE-3和抑癌基因p53在肺癌中表达的研究[J].现代肿瘤医学,2007,15(8):1106-1108. 被引量:8
  • 4Cerfolio RJ,Bryant AS.Survival of Patients With Unsuspected N2 (Stage ⅢA) Nonsmall-Cell Lung Cancer.Ann Thorac Surg,2008,86(2):362-367.
  • 5van Meerbeeck JP,Kramer GW,Van Schil PE,et al.Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage Ⅲ A-N2 non-small-cell lung cancer.J Natl Cancer Inst,2007,99(6):442-450.
  • 6Burdett S,Stewart LA,Rydzewska L.A systematic review and metaanalysis of the literature:chemotherapy and surgery versus surgery alone in non-small cell lung cancer.J Thorac Oncol,2006,1 (7):611-621.
  • 7Tieu BH,Sanbom RE,Thomas CR Jr.Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.Thorac Surg Clin,2008,18(4):403-415.
  • 8Gilligan D,Nicolson M,Smith I,et al.Preoperative chemotherapy in patients with resectable non-small cell lung cancer:results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.Lancet,2007,369 (9577):1929-1937.
  • 9Westeel V,Milleron B,Quoix E,et al.Results of the IFCT 0002phase Ⅲ study comparing a preoperative and a perioperative chemotherapy (CT) with two different CT regimens in resectable non-small cell lung cancer (NSCLC).J Clin Oncol,2009,27 (15S,part1):Abstract 7530.
  • 10Pisters K,Vallieres E,Bunn PA,et al.S9900:Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC):Follow-up on a phase Ⅲ trial.J Clin Oncol,2007,25(18S,part1):Abstract 7520.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部